Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Svenja Wagener‐Ryczek"'
Autor:
Martin Thelen, Kerstin Wennhold, Jonas Lehmann, Maria Garcia-Marquez, Sebastian Klein, Elena Kochen, Philipp Lohneis, Axel Lechner, Svenja Wagener-Ryczek, Patrick Sven Plum, Oscar Velazquez Camacho, David Pfister, Fabian Dörr, Matthias Heldwein, Khosro Hekmat, Dirk Beutner, Jens Peter Klussmann, Fabinshy Thangarajah, Dominik Ratiu, Wolfram Malter, Sabine Merkelbach-Bruse, Christiane Josephine Bruns, Alexander Quaas, Michael von Bergwelt-Baildon, Hans A. Schlößer
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-12 (2021)
Abstract The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells a
Externí odkaz:
https://doaj.org/article/4edee7d56ead4b1585567524e79d56a7
Autor:
Carina Heydt, Christina B. Wölwer, Oscar Velazquez Camacho, Svenja Wagener-Ryczek, Roberto Pappesch, Janna Siemanowski, Jan Rehker, Florian Haller, Abbas Agaimy, Karl Worm, Thomas Herold, Nicole Pfarr, Wilko Weichert, Thomas Kirchner, Andreas Jung, Jörg Kumbrink, Wolfgang Goering, Irene Esposito, Reinhard Buettner, Axel M. Hillmer, Sabine Merkelbach-Bruse
Publikováno v:
BMC Medical Genomics, Vol 14, Iss 1, Pp 1-14 (2021)
Abstract Background Gene fusions represent promising targets for cancer therapy in lung cancer. Reliable detection of multiple gene fusions is therefore essential. Methods Five commercially available parallel sequencing assays were evaluated for thei
Externí odkaz:
https://doaj.org/article/44bdb1f0d72743ee9374126053306f77
Autor:
Svenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, Sebastian Michels, Markus Falk, Christina Alidousty, Jana Fassunke, Michaela Angelika Ihle, Markus Tiemann, Lukas Heukamp, Jürgen Wolf, Reinhard Büttner, Sabine Merkelbach-Bruse
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd –generation irreversible EGFR TKI Afatinib were aimed to improve treatment resp
Externí odkaz:
https://doaj.org/article/f7936ba47ab04f9d9e1b464f58d1640a
Autor:
Carina Heydt, Ann-Kathrin Becher, Svenja Wagener-Ryczek, Markus Ball, Anne M. Schultheis, Simon Schallenberg, Vanessa Rüsseler, Reinhard Büttner, Sabine Merkelbach-Bruse
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 17, Iss , Pp 1339-1347 (2019)
In EGFR-treatment naive NSCLC patients, high-level MET amplification is detected in approximately 2–3% and is considered as adverse prognostic factor. Currently, clinical trials with two different inhibitors, capmatinib and tepotinib, are under way
Externí odkaz:
https://doaj.org/article/1d0261c414844447ae380ed7d10134fd
Autor:
Sebastian Klein, Oana-Diana Persa, Cornelia Mauch, Ka-Won Noh, Roberto Pappesch, Svenja Wagener-Ryczek, Reinhard Buettner, Alexander Quaas, Doris Helbig
Publikováno v:
OncoImmunology, Vol 8, Iss 12 (2019)
Pleomorphic dermal sarcoma (PDS) is one of the most common sarcoma of the skin. Currently, limited treatment options exist for advanced stages of the disease. While immune checkpoint inhibitors (CPIs) have revolutionized cancer treatment options–th
Externí odkaz:
https://doaj.org/article/1815d6c0b60940589ea534359a70ce96
Autor:
Tim Nestler, Lara Kremer, Melanie von Brandenstein, Maike Wittersheim, Pia Paffenholz, Svenja Wagener‐Ryczek, Alexander Quaas, Martin Hellmich, Stefan Müller, David Pfister, Margarete Odenthal, Axel Heidenreich
Publikováno v:
Cancer. 129:634-642
Before postchemotherapy retroperitoneal lymph node dissection (pcRPLND), in patients with metastasized germ cell tumors (GCTs), those harboring necrosis (NEC) cannot be distinguished from those who have teratoma (TER), resulting in relevant overtreat
Autor:
Claudia Vollbrecht, Inga Hoffmann, Annika Lehmann, Sabine Merkelbach-Bruse, Jana Fassunke, Svenja Wagener-Ryczek, Markus Ball, Lora Dimitrova, Arndt Hartmann, Robert Stöhr, Ramona Erber, Wilko Weichert, Nicole Pfarr, Lisa Bohlmann, Andreas Jung, Wolfgang Dietmaier, Manfred Dietel, David Horst, Michael Hummel
Publikováno v:
Virchows Archiv. 482:697-706
Precision oncology based on specific molecular alterations requires precise and reliable detection of therapeutic targets in order to initiate the optimal treatment. In many European countries—including Germany—assays employed for this purpose ar
Autor:
Tim Nestler, Lara Kremer, Melanie Von Brandenstein, Maike Wittersheim, Svenja Wagener-Ryczek, Pia Paffenholz, Stefan Mueller, Alexander Quaas, Martin Hellmich, Margarete Odenthal, David Pfister, Axel Heidenreich
Publikováno v:
Journal of Urology. 209
Autor:
Tim Nestler, Priya Dalvi, Friederike Haidl, Maike Wittersheim, Melanie von Brandenstein, Pia Paffenholz, Svenja Wagener-Ryczek, David Pfister, Ulrike Koitzsch, Martin Hellmich, Reinhard Buettner, Margarete Odenthal, Axel Heidenreich
Publikováno v:
British Journal of Cancer. 126:937-947
Background Testicular germ cell tumours (TGCTs) have a high metastasis rate. However, the mechanisms related to their invasion, progression and metastasis are unclear. Therefore, we investigated gene expression changes that might be linked to metasta
Autor:
Richard Riedel, Jana Fassunke, Hannah L. Tumbrink, Andreas H. Scheel, Carina Heydt, Lena Hieggelke, Matthias Scheffler, Alena Heimsoeth, Lucia Nogova, Sebastian Michels, Jan-Phillip Weber, Rieke N. Fischer, Anna Eisert, Theresa Westphal, Diana Schaufler, Janna Siemanowski, Michaela A. Ihle, Svenja Wagener-Ryczek, Roberta Castiglione, Roberto Pappesch, Jan Rehker, Jessica Jürgens, Erich Stoelben, Anne Bunck, Carsten Kobe, Sabine Merkelbach-Bruse, Martin L. Sos, Reinhard Büttner, Jürgen Wolf
Publikováno v:
European journal of cancer (Oxford, England : 1990). 179
Resistance to MET inhibition occurs inevitably in MET-dependent non-small cell lung cancer and the underlying mechanisms are insufficiently understood. We describe resistance mechanisms in patients with MET exon 14 skipping mutation (METΔPre- and po